AB0951 EFFICACY AND SAFETY OF UPADACITINIB IN ANKYLOSING SPONDYLITIS. REAL WORLD DATA

Background Upadacitinib is a selective and reversible inhibitor of Janus Kinases (JAKs) that preferentially inhibits signaling via JAK1 or JAK1/3. JAK1 inhibition with upadacitinib modulates JAK-dependet cytokine signaling, thereby decreasing the inflammatory burden of different immune-mediated diseases. Upadacitinib is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis (radiographic axial spondyloarthritis), ulcerative colitis, and atopic dermatitis. In the case of ankylosing spondylitis, the drug has been approved for use in Spain since March 2022. Objectives The present study aims to evaluate the first data on safety and efficacy of upadacitinib use in ankylosing spondylitis in real clinical practice. Methods Retrospective observational multicenter study that included patients of 8 Spanish hospitals. Demographic data, personal history, and clinical course of patients diagnosed with ankylosing spondylitis treated with upadacitinib at participating centers were collected. Results Forty-four patients with ankylosing spondylitis who received upadacitinib for a mean time (SD) of 8.7 (7.4) months were included in the study. They had received previous biological treatments in 86 % of cases, 30% of patients at least 5. An improvement was observed in 70 % of patients as measured by subjective patient-reported improvement. The treatment was suspended in the 27.3% of patients, the main reason for suspension was inefficacy. A higher percentage of suspension was found in patients who had received a greater number of previous biological treatments. Adverse effects were reported in 8 patients, the most serious being one episode of tachyarrhythmia, one episode of deep vein thrombosis, one episode of peptic ulcer and one episode of herpes zoster, and the most frequent adverse effect being headache. Conclusion 70% of patients with ankylosing spondylitis who received upadacitinib for a median time of 8.7 months experienced subjective improvement in their symptoms. Acknowledgements Acknowledgements to all collaborators. Disclosure of Interests None Declared.